AI medical device companies face major reimbursement hurdles when trying to secure coverage, CPT codes, and payment from ...

Revenue Guidance -- Management reiterated full-year fiscal 2025 revenue guidance of $26 million to $30 million and set Q4 fiscal 2025 outlook to $7.5 million to $7.9 million.

Q3 2025 Earnings Call Transcript November 13, 2025 Bionano Genomics, Inc. beats earnings expectations. Reported EPS is $-1.59292, expectations were $-1.81. Operator: Good day, and welcome to the ...

Medical offices bill insurance providers for clients' services. Learn what's involved, including HIPAA regulations, what to include and what can go wrong.

Conference call will be held today, Tuesday, November 11 at 9:00 am ETCARMEL, Ind., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical ...

NeurAxis, Inc. ('NeurAxis” or the 'Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and ...

You hear about AI changing things everywhere, and medicine is no different. One area where it’s really making a difference is ...

Integrating Nym AI requires a clear plan that looks at both the technology and the people involved. By assessing current workflows, implementing in stages, and preparing your team for new ...

The new Category III code, CPT 1019T Lymphovenous bypass, including robotic assistance, when performed, per extremity, will become effective in the U.S. on January 1, 2026.

New CPT code changes for invasive cardiology and interventional radiology will take effect on January 1, 2026, with a ...

The SWE-Bench Verified evaluation is basically a test of AI processing accuracy. It measures how well the AI solves a set of coding problems. According to OpenAI, GPT-5.1-Codex-Max "reaches the same ...

GPT-5.1-Codex-Max is OpenAI’s latest frontier agentic coding model, and it’s faster and more intelligent and efficient than previous models.